ArticleRenal failure2024
Changes in the spectrum of biopsy-proven renal diseases over 11 years: a single-center study in China.
Article in Renal failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Kidney biopsy in patients with small kidneys: diagnostic yield and treatment modification in a retrospective cohort study.Renal failure · 2026Article
- Spectrum of biopsy-proven kidney diseases in 3514 patients at a single center in Northwest China from 2014 to 2023.Clinical and experimental nephrology · 2026Article
- The Spectrum of Biopsy-Proven Renal Diseases in Chinese Elderly Patients and Its Temporal Shift Over 20 Years: A Retrospective Cohort Study.Aging medicine (Milton (N.S.W)) · 2026Article
- Mafu Yishen Formula ameliorates membranous nephropathy by promotion of regulatory T cell differentiation: a multi-omics study.Chinese medicine · 2026Article
- Targeted release of budesonide modulates key gut microbial abnormalities in immunoglobulin A nephropathy.Frontiers in immunology · 2026Article
- Article
- Renal histopathology spectrum in the biopsy-proven native kidney diseases of adult Iranian population, southern Iran: 2019-2024.Caspian journal of internal medicine · 2026Article
- A multicenter retrospective cohort study on the efficacy and safety of mycophenolate mofetil plus hydroxychloroquine therapy in IgA nephropathy.Frontiers in immunology · 2026Article
- Immunofluorescence staining profiles of glomerular diseases: a single-center retrospective study.Biochemistry and biophysics reports · 2025Article
- Artificial intelligence-assisted diagnosis of glomerular nephritis using a pathological image analysis approach: a multicentre model development and validation study.EClinicalMedicine · 2025Article
- A retrospective single-center cohort study of major subtypes of primary glomerular diseases (MN, IgAN, and MCD): clinical characteristics, prognostic outcomes, and risk factors.Frontiers in medicine · 2025Article
- Efficacy and safety of ripertamab for treating primary membranous nephropathy among adults: a multicenter, retrospective, real-world study.Frontiers in immunology · 2025Observational
- Renal arteriolosclerosis impact on clinicopathological features and outcomes of idiopathic membranous nephropathy: a retrospective cohort analysis.Frontiers in medicine · 2025Article
- The dysbiosis of gut microbiota and dysregulation of metabolites in IgA nephropathy and membranous nephropathy.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere have been some shifts in the frequency and distribution of biopsy-proven renal diseases in China over recent years. The aim of the study was to investigate the changing spectrum of renal diseases from the view of kidney biopsy data in a single center of China. METHODS AND
resultsA total of 10,996 cases of native renal biopsies from patients aged ≥15 years old in Huashan Hospital, Fudan University, between 2008 and 2018 were analyzed retrospectively. The results showed that primary glomerular nephropathy (PGN) remained the most common biopsy-proven renal disease (69.42% of total), with IgA nephropathy (IgAN) accounting for 44.40% of PGN, membranous nephropathy (MN) for 28.55%, minimal change disease (MCD) for 13.26% and focal segmental glomerulosclerosis (FSGS) for 8.00%. During the study period, the proportion of MN in PGN appeared an increasing tendency, while that of IgAN and MCD remained stable and that of FSGS showed a decline. Secondary glomerular nephropathy (SGN) constituted 21.54% of total cases, among which the leading two diseases were lupus nephritis (LN) and Henoch-Schonlein purpura nephritis (HSN) which accounted for 41.08% and 19.11% respectively.
conclusionsThe 11-year retrospective study revealed that PGN was the predominant histologic diagnosis among patients undergoing renal biopsy and the most frequent type of PGN remained to be IgAN, followed by MN which increased dramatically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.